Åhman Ada, Berge Jonas, Håkansson Anders
Department of Clinical Sciences Lund, Division of Psychiatry, Faculty of Medicine, Lund University, Lund, Sweden.
Front Cardiovasc Med. 2025 Jan 24;12:1378833. doi: 10.3389/fcvm.2025.1378833. eCollection 2025.
Amphetamine use is an increasing problem, and studies suggest a connection between amphetamine use and cardiovascular and cerebrovascular pathology. However, few long-term studies examine amphetamine users' risk of cardiovascular and cerebrovascular pathology, in comparison to users of other drugs. In addition, in a criminal justice system, illicit drug use and psychiatric comorbidity is common, whereas structured treatment and follow-up is uncommon, and stimulant use is common in this setting. The aim of this study was to investigate the risk of cardiovascular and cerebrovascular morbidity and mortality for intravenous drug users with different drugs as the primary drug, using data from the criminal justice system.
A cohort of injecting substance users ( = 2,422) was identified in the Swedish criminal justice system through interviews with the Addiction Severity Index (ASI) between January 2001 and August 2006. Data on age, sex, self-reported injection drug, tobacco use, and time in prison or custody were retrieved from the ASI database. The clients were followed in national registers up to 2014 with respect to cardiovascular and cerebrovascular morbidity and mortality. Potential predictors of cardiovascular and cerebrovascular events were investigated.
Self-reported main drug was amphetamine in 51.5% ( = 1,247), polysubstance use in 33% ( = 799), and heroin in 15.5% ( = 376) of the cohort. Total observational time for the entire cohort was 23,911 person-years [median 10.3 years (IQR 9.3-11.2 years)]. The highest incidence rates of both cardiovascular and cerebrovascular events were found among amphetamine users. Bivariate analyses showed a significantly higher percentage of cardiovascular events in amphetamine users compared to other substance users ( < 0.044). Amphetamine was not significantly associated with cardiovascular or cerebrovascular events, compared to the main drug heroin or polysubstance use.
In this study on substance-using criminal justice clients, while the highest incidence rates of both cardiovascular and cerebrovascular events were found among amphetamine-using individuals, the study did not provide evidence of an independent association. The study highlights the need to take co-factors into account, such as comorbidities and socio-economic factors. More studies are needed to distinguish substance-specific pathology from the impact of other unhealthy lifestyle factors among substance-using individuals.
苯丙胺的使用问题日益严重,研究表明苯丙胺使用与心血管和脑血管病变之间存在关联。然而,与其他药物使用者相比,很少有长期研究考察苯丙胺使用者发生心血管和脑血管病变的风险。此外,在刑事司法系统中,非法药物使用和精神疾病共病很常见,而结构化治疗和随访却不常见,且在这种情况下兴奋剂使用也很常见。本研究的目的是利用刑事司法系统的数据,调查以不同药物作为主要药物的静脉吸毒者发生心血管和脑血管发病及死亡的风险。
2001年1月至2006年8月期间,通过对成瘾严重程度指数(ASI)进行访谈,在瑞典刑事司法系统中确定了一组注射吸毒者(n = 2422)。从ASI数据库中获取了年龄、性别、自我报告的注射药物、烟草使用情况以及在监狱或拘留所的时间等数据。对这些对象在国家登记处进行随访,直至2014年,了解其心血管和脑血管发病及死亡情况。对心血管和脑血管事件的潜在预测因素进行了调查。
该队列中自我报告的主要药物为苯丙胺的占51.5%(n = 1247),多药合用的占33%(n = 799),海洛因的占15.5%(n = 376)。整个队列的总观察时间为23911人年[中位数10.3年(四分位间距9.3 - 11.2年)]。在苯丙胺使用者中发现心血管和脑血管事件的发病率最高。双变量分析显示,与其他物质使用者相比,苯丙胺使用者中心血管事件的百分比显著更高(p < 0.044)。与主要药物海洛因或多药合用相比,苯丙胺与心血管或脑血管事件无显著关联。
在这项针对使用毒品的刑事司法对象的研究中,虽然在使用苯丙胺的个体中发现心血管和脑血管事件的发病率最高,但该研究并未提供独立关联的证据。该研究强调需要考虑共病和社会经济因素等共同因素。需要更多研究来区分物质特异性病变与使用毒品个体中其他不健康生活方式因素的影响。